Legal & General Group Plc Lowers Stock Position in Altimmune, Inc. (NASDAQ:ALT)

Legal & General Group Plc lessened its holdings in shares of Altimmune, Inc. (NASDAQ:ALT) by 8.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 68,102 shares of the company’s stock after selling 6,046 shares during the period. Legal & General Group Plc owned 0.10% of Altimmune worth $491,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of ALT. Virtu Financial LLC bought a new stake in shares of Altimmune in the 3rd quarter worth approximately $674,000. Barclays PLC boosted its holdings in Altimmune by 93.0% in the third quarter. Barclays PLC now owns 155,741 shares of the company’s stock worth $956,000 after acquiring an additional 75,064 shares in the last quarter. Stifel Financial Corp boosted its holdings in Altimmune by 77.4% in the third quarter. Stifel Financial Corp now owns 17,752 shares of the company’s stock worth $109,000 after acquiring an additional 7,746 shares in the last quarter. SBI Securities Co. Ltd. purchased a new stake in shares of Altimmune in the fourth quarter worth $45,000. Finally, LPL Financial LLC increased its holdings in shares of Altimmune by 15.2% during the fourth quarter. LPL Financial LLC now owns 58,173 shares of the company’s stock valued at $419,000 after acquiring an additional 7,693 shares in the last quarter. 78.05% of the stock is currently owned by institutional investors.

Altimmune Stock Up 0.8 %

ALT opened at $5.10 on Wednesday. Altimmune, Inc. has a twelve month low of $3.55 and a twelve month high of $11.16. The stock has a market capitalization of $392.77 million, a price-to-earnings ratio of -3.29 and a beta of 0.91. The firm has a 50 day moving average price of $5.21 and a 200-day moving average price of $6.68.

Altimmune (NASDAQ:ALT) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.01. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. As a group, analysts expect that Altimmune, Inc. will post -1.35 earnings per share for the current year.

Insider Buying and Selling at Altimmune

In other Altimmune news, CFO Gregory L. Weaver acquired 10,000 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The shares were bought at an average price of $5.20 per share, with a total value of $52,000.00. Following the completion of the acquisition, the chief financial officer now owns 10,000 shares in the company, valued at $52,000. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.10% of the company’s stock.

Wall Street Analysts Forecast Growth

ALT has been the topic of a number of analyst reports. Stifel Nicolaus began coverage on shares of Altimmune in a research note on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Altimmune in a research note on Thursday, April 3rd. Finally, William Blair reissued a “market perform” rating on shares of Altimmune in a research report on Friday, March 14th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Altimmune presently has an average rating of “Buy” and a consensus target price of $20.83.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.